# **SAFETY DATA SHEETS**

# This SDS packet was issued with item: 078948459

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078948450 078948453 078948455 078948457 078948458



According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

Initial Preparation Date: 07.19.2023

Delaquin™ (marbofloxacin) Chewable Tablets 25mg, 50mg, 100mg and 200mg (RX)

#### **SECTION 1: Identification**

## **Product Identifier**

Product Name: Delaquin™ (marbofloxacin) Chewable Tablets 25mg, 50mg, 100mg and 200mg (RX)Product code: 21311414, 21311415, 21311416, 21311417, 21311418, 21311419

#### **Recommended Use of the Product and Restriction on Use**

**Relevant Identified Uses:** Marbofloxacin Chewable Tablets are indicated for the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

**Uses Advised Against:** Any use other than recommended above. **Reasons Why Uses Advised Against:** Not determined or not applicable.

#### **Manufacturer or Supplier Details**

#### Supplier: United States Aspen Veterinary Resources, LTD. 3155 W. Heartland Drive Liberty, MO 64068 1-800-792-1238

# **Emergency Telephone Number:**

United States CHEMTREC Within USA and Canada: 1-800-424-9300 (24 hours) Outside USA and Canada: +1-703-527-3887 (24 hours)

#### SECTION 2: Hazard(s) Identification

GHS Classification: Not a hazardous substance or mixture Label elements

Hazard Pictograms: None

Signal Word: None

Hazard statements: None Precautionary Statements: None Hazards Not Otherwise Classified: None

#### **SECTION 3: Composition/Information on Ingredients**

Identification	Name	Weight %
CAS Number: 115550-35-1	Marbofloxacin	10-15

Page 1 of 8

According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

Initial Preparation Date: 07.19.2023

Page 2 of 8

## Delaquin™ (marbofloxacin) Chewable Tablets 25mg, 50mg, 100mg and 200mg (RX)

# Additional Information:

The specific chemical identity and/or exact percentage (concentration) of composition has been withheld as a trade secret in accordance with paragraph (i) of the OSHA Hazard Communication Standard (29 CFR §1910.1200).

# **SECTION 4: First Aid Measures**

# **Description of First Aid Measures**

# **General Notes:**

If you feel unwell, seek medical advice, Show this Safety Data Sheet to the doctor in attendance.

#### After Inhalation:

Not an expected route of exposure. In case of over exposure, move exposed person to fresh air. Refer to a physician if subject experiences difficulty breathing.

#### After Skin Contact:

Remove contaminated clothing and shoes. Wash skin with soap and water. This material may not be completely removed by conventional laundering. Consult professional laundry service. Do not home launder. If irritation occurs or persists, get medical attention.

#### After Eye Contact:

Immediately rinse eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 15 minutes. If eye irritation develops or persists, seek medical advice/attention.

#### After Swallowing:

Get medical attention. Do not induce vomiting unless directed by medical personnel. Rinse mouth with water. Never give anything by mouth to an unconscious person. If spontaneous vomiting occurs, place on the left side with head down to prevent aspiration of liquid into the lungs.

#### Most Important Symptoms and Effects, Both Acute and Delayed

#### Acute Symptoms and Effects:

IF INHALED: Due to the product's final form, inhalation is an unlikely route of exposure.

IN CONTACT WITH SKIN: Prolonged skin contact may cause mild irritation.

IN CONTACT WITH EYES: Prolonged eye contact may result in irritation.

IF INGESTED: Fluoroquinolones may cause disorders of the central nervous system and connective tissue structures. The most common adverse reactions associated with the use of quinolones include gastrointestinal distress, such as nausea or diarrhea, and central nervous system (CNS) effects, including insomnia, dizziness, and seizures. Sensory/motor nerve injury (peripheral neuropathy) may occur.

#### **Delayed Symptoms and Effects:**

None expected under normal conditions of use

#### **Immediate Medical Attention and Special Treatment**

#### **Specific Treatment:**

Not determined or not applicable.

#### Notes for the Doctor:

Treat symptomatically.

# **SECTION 5: Firefighting Measures**

# Extinguishing Media

#### Suitable Extinguishing Media:

Select extinguishing media suitable for surrounding area.

## **Unsuitable Extinguishing Media:**

According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

#### Initial Preparation Date: 07.19.2023

#### Delaquin™ (marbofloxacin) Chewable Tablets 25mg, 50mg, 100mg and 200mg (RX)

There is no restriction on the type of extinguisher which may be used.

#### **Specific Hazards During Fire-Fighting:**

Fine particles (such as dust and mists) may fuel fires/explosions. Thermal decomposition may produce irritating/toxic fumes/gases.

## Special Protective Equipment for Firefighters:

Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA).

# Special precautions:

Use water delivered as a fine spray to control fire and cool adjacent area. Do not approach containers suspected to be hot. Cool fire exposed containers with water spray from a protected location. If safe to do so, remove containers from path of fire. Equipment should be thoroughly decontaminated after use. Avoid unnecessary run-off of extinguishing media which may cause pollution.

## **SECTION 6: Accidental Release Measures**

#### Personal Precautions, Protective Equipment, and Emergency Procedures:

Evacuate unnecessary personnel. Ventilate area. Extinguish any sources of ignition. Wear recommended personal protective equipment (see Section 8). Avoid contact with skin, eyes and clothing. Avoid breathing mist, vapor, dust, fume and spray. Do not walk through spilled material. Wash thoroughly after handling.

#### **Environmental Precautions:**

Prevent further leakage or spillage if safe to do so. Prevent from reaching drains, sewers and waterways. Discharge into the environment must be avoided.

# Methods and Material for Containment and Cleaning Up:

Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. Place recovered material in suitable container for future disposal. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly. Dispose of in accordance with all applicable regulations (see Section 13).

#### **Reference to Other Sections:**

For personal protective equipment see Section 8. For disposal see Section 13.

#### **SECTION 7: Handling and Storage**

# **Precautions for Safe Handling:**

Use appropriate personal protective equipment (see Section 8). Keep away from heat. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. Avoid generating airborne dust. Keep away from heat, sparks, and flame. Do not eat, drink, smoke, or use personal products when handling chemical substances. Wash affected areas thoroughly after handling. Keep away from incompatible materials (See Section 10). Keep containers tightly closed when not in use.

#### Conditions for Safe Storage, Including Any Incompatibilities:

Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C (between 59° and 86°F). [See USP controlled room temperature]. Store tablets in a tight container only.

#### **SECTION 8: Exposure Controls/Personal Protection**

Only those substances with limit values have been included below.

#### **Occupational Exposure Limit Values:**

No occupational exposure limits noted for the ingredient(s).

#### **Biological Limit Values:**

No biological exposure limits noted for the ingredient(s).

#### Information on Monitoring Procedures:

Not determined or not applicable.

According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

Initial Preparation Date: 07.19.2023

Delaquin™ (marbofloxacin) Chewable Tablets 25mg, 50mg, 100mg and 200mg (RX)

# **Appropriate Engineering Controls:**

Emergency eye wash stations and safety showers should be available in the immediate vicinity of use or handling. Provide adequate ventilation to maintain the airborne concentrations of vapor, mists, and/or dusts below the applicable workplace exposure limits, while observing recognized national standards (or equivalent).

# **Personal Protection Equipment**

# Eye and Face Protection:

Safety glasses or goggles. Use eye protection equipment that has been tested and approved by recognized national standards (or equivalent).

# Skin and Body Protection:

Chemical resistant, impervious gloves approved by the appropriate standards. Gloves must be inspected prior to use. Avoid skin contact with used gloves. Appropriate techniques should be used to remove used gloves and contaminated clothing. Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. Ensure that all personal protective equipment is approved by recognized national standards (or equivalent).

#### **Respiratory Protection:**

If engineering controls do not maintain airborne concentrations below the applicable workplace exposure limits, or to an acceptable level (if exposure limits have not been established), a respirator approved by recognized national standards (or equivalent) must be worn.

#### **General Hygienic Measures:**

When handling chemical products, do not eat, drink or smoke. Wash hands after handling, before breaks, and at the end of the workday. Avoid contact with skin, eyes and clothing. Wash contaminated clothing before reuse. Perform routine housekeeping.

# **SECTION 9: Physical and Chemical Properties**

#### Information on Basic Physical and Chemical Properties

Apportance	Round chewable tablets; Off white to brown, mottled color
Appearance	
Odor	Not determined or not available.
Odor threshold	Not determined or not available.
рН	Not determined or not available.
Melting point/freezing point	Not determined or not available.
Initial boiling point/range	Not determined or not available.
Flash point (closed cup)	Not determined or not available.
Evaporation rate	Not determined or not available.
Flammability (solid, gas)	Not determined or not available.
Upper flammability/explosive limit	Not determined or not available.
Lower flammability/explosive limit	Not determined or not available.
Vapor pressure	Not determined or not available.
Vapor density	Not determined or not available.
Density	Not determined or not available.
Relative density	Not determined or not available.
Solubilities	Not determined or not available.
Partition coefficient (n-octanol/water)	Not determined or not available.
Auto/Self-ignition temperature	Not determined or not available.
Decomposition temperature	Not determined or not available.

According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

Initial Preparation Date: 07.19.2023

Delaquin™ (marbofloxacin) Chewable Tablets 25mg, 50mg, 100mg and 200mg (RX)

Dynamic viscosity	Not determined or not available.
Kinematic viscosity	Not determined or not available.
Explosive properties	Not determined or not available.
Oxidizing properties	Not determined or not available.

# **SECTION 10: Stability and Reactivity**

#### **Reactivity:**

Not reactive under recommended handling and storage conditions.

#### Chemical Stability:

Stable under recommended handling and storage conditions.

#### **Possibility of Hazardous Reactions:**

Hazardous reactions are not anticipated under recommended conditions of handling and storage.

#### **Conditions to Avoid:**

Extreme heat, open flames, hot surfaces, sparks, ignition sources, dust generation and incompatible materials

#### Incompatible Materials:

None Known.

## **Hazardous Decomposition Products:**

Under normal conditions of storage and use, hazardous decomposition products should not be produced.

#### **SECTION 11: Toxicological Information**

#### Acute Toxicity

Assessment: Based on available data, the classification criteria are not met.

## Product Data:

Route	Result	
Oral	LD50 Rat: > 2720-3772 mg/kg	
	LD50 Mouse: > 1781-1822 mg/kg	

#### Substance Data: No data available.

#### **Skin Corrosion/Irritation**

Assessment: Based on available data, the classification criteria are not met.

Product Data:

No data available.

Substance Data: No data available.

#### Serious Eye Damage/Irritation

Assessment: Based on available data, the classification criteria are not met.

Product Data:

No data available.

Substance Data: No data available.

# **Respiratory or Skin Sensitization**

Assessment: Based on available data, the classification criteria are not met.

Product Data:

No data available.

Substance Data: No data available.

# Carcinogenicity

Assessment: Based on available data, the classification criteria are not met.

According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

Initial Preparation Date: 07.19.2023 Delaquin™ (marbofloxacin) Chewable Tablets 25mg, 50mg, 100mg and 200mg (RX) Product Data: No data available. Substance Data: No data available. International Agency for Research on Cancer (IARC): None of the ingredients are listed. National Toxicology Program (NTP): None of the ingredients are listed. **OSHA Carcinogens:** Not applicable Germ Cell Mutagenicity Assessment: Based on available data, the classification criteria are not met. Product Data: No data available. Substance Data: No data available. **Reproductive Toxicity** Assessment: Based on available data, the classification criteria are not met. **Product Data:** No data available. Substance Data: No data available.

# Specific Target Organ Toxicity (Single Exposure)

**Assessment:** Based on available data, the classification criteria are not met.

# Product Data:

No data available.

Substance Data: No data available.

#### Specific Target Organ Toxicity (Repeated Exposure)

**Assessment:** Based on available data, the classification criteria are not met.

#### **Product Data:**

No data available.

Substance Data: No data available.

#### Aspiration toxicity

Assessment: Based on available data, the classification criteria are not met.

#### Product Data:

No data available.

Substance Data: No data available.

#### Information on Likely Routes of Exposure:

Ingestion; Skin contact; Eye contact

#### Symptoms Related to the Physical, Chemical, and Toxicological Characteristics:

Refer to Section 4 of this SDS.

#### Other Information:

No data available.

#### **SECTION 12: Ecological Information**

Acute (Short-Term) Toxicity Assessment: Based on available data, the classification criteria are not met. Product Data: No data available. Substance Data: No data available. Chronic (Long-Term) Toxicity Assessment: Based on available data, the classification criteria are not met. Product Data: No data available. Substance Data: No data available. Persistence and Degradability

Product Data: No data available.

According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

#### Initial Preparation Date: 07.19.2023

#### Delaquin™ (marbofloxacin) Chewable Tablets 25mg, 50mg, 100mg and 200mg (RX)

Substance Data: No data available.

## **Bioaccumulative Potential**

Product Data: No data available.

Substance Data: No data available.

#### **Mobility in Soil**

Product Data: No data available.

Substance Data: No data available.

#### **Results of PBT and vPvB assessment**

#### **Product Data:**

**PBT assessment:** This product does not contain any substances that are assessed to be a PBT. **vPvB assessment:** This product does not contain any substances that are assessed to be a vPvB.

#### Substance Data:

**PBT assessment:** This product does not contain any substances that are assessed to be a PBT. **vPvB assessment:** This product does not contain any substances that are assessed to be a vPvB.

#### Other Adverse Effects: No data available.

#### **SECTION 13: Disposal Considerations**

#### **Disposal Methods:**

It is the responsibility of the waste generator to properly characterize all waste materials according to applicable regulatory agencies. Dispose of in accordance with all applicable local, regional, state and federal regulations.

#### Contaminated packages:

Not determined or not applicable.

#### **SECTION 14: Transport Information**

#### United States Transportation of Dangerous Goods (49 CFR DOT)

UN Number	Not regulated
UN Proper Shipping Name	Not regulated
UN Transport Hazard Class(es)	None
Packing Group	None
Environmental Hazards	None
Special Precautions for User	None

#### International Maritime Dangerous Goods (IMDG)

UN Number	Not regulated
UN Proper Shipping Name	Not regulated
UN Transport Hazard Class(es)	None
Packing Group	None
Environmental Hazards	None
Special Precautions for User	None

#### International Air Transport Association Dangerous Goods Regulations (IATA-DGR)

UN Number	Not regulated
UN Proper Shipping Name	Not regulated
UN Transport Hazard Class(es)	None

According to OSHA Hazard Communication Standard, 29 CFR 1910.1200

# Initial Preparation Date: 07.19.2023

Delaquin™ (marbofloxacin) Chewable Tablets 25mg, 50mg, 100mg and 200mg (RX)

Packing Group	None
Environmental Hazards	None
Special Precautions for User	None

# **SECTION 15: Regulatory Information**

# **United States Regulations**

**Inventory Listing (TSCA):** None of the ingredients are listed.

Significant New Use Rule (TSCA Section 5): None of the ingredients are listed.

Export Notification under TSCA Section 12(b): None of the ingredients are listed.

SARA Section 302 Extremely Hazardous Substances: None of the ingredients are listed.

SARA Section 313 Toxic Chemicals: None of the ingredients are listed.

**CERCLA:** None of the ingredients are listed.

**RCRA:** None of the ingredients are listed.

Section 112(r) of the Clean Air Act (CAA): None of the ingredients are listed.

Massachusetts Right to Know: None of the ingredients are listed.

**New Jersey Right to Know:** None of the ingredients are listed.

New York Right to Know: None of the ingredients are listed.

Pennsylvania Right to Know: None of the ingredients are listed.

California Proposition 65: None of the ingredients are listed.

Additional information: Not determined.

# **SECTION 16: Other Information**

# Abbreviations and Acronyms: None

# **Disclaimer:**

This product has been classified in accordance with OSHA HCS 2012 guidelines. The information provided in this SDS is correct, to the best of our knowledge, based on information available. The information given is designed only as a guidance for safe handling, use, storage, transportation and disposal and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials, unless specified in the text. The responsibility to provide a safe workplace remains with the user.

# Initial Preparation Date: 07.19.2023

# **End of Safety Data Sheet**